Marcel Hop, PhD, Vice President, DMPK, Genentech

Influencing Design with in silico ADME Models

Kathy Giacomini, PhD, Professor, Bioengineering, Co-Director UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation, School of Pharmacy, UCSF

High Throughput Screening and Real World Biomarkers to Predict Drug-Drug and Drug-Nutrient Interactions: Implications to poly pharmacy associated with COVID

Yurong Lai, Gilead, PhD, FAAPS, Sr. Director, Drug Metabolism, Gilead Sciences

Title TBA - ADME data on Remdesivir/treatment efficacy

David Rodrigues, PhD, Senior Scientific Director, Head of Transporter Sciences Group, Pfizer

Liquid Biopsy in ADME: Where are We Now and Where are We Going?

Dallas Bednarczyk, PhD, Senior Principal Scientist, Novartis Institutes for Biomedical Research

The Impact of Ion Trapping on the Cellular Accumulation of Highly Permeable Low Molecular Weight Acidic Drugs

Bo Feng, PhD, Director, DMPK, Vertex Pharmaceuticals

Validation of PXB Chimeric Mice with Humanized Liver to Predict Human Liver-to-Plasma Kpuu of OATP1B1 Substrates

Na Li, PhD, Senior Research Scientist II, C4 Therapeutics

Improved IVIVE for Hepatic Clearance Prediction: The Impact of Albumin on Hepatic Uptake

Iain Martin, Vice President, DMPK, Relay Therapeutics 

Unbound Volume of Distribution as a Foundational Parameter in Drug Design

Randy Miller, Senior Investigator, Merck

Unbound Volume of Distribution as a Foundational Parameter in Drug Design

Mark Milton, PhD, Ophthalmology Therapeutic Area Head, PK Sciences at Novartis Institutes for BioMedical Research (NIBR)

AAV Gene Therapies - New Opportunities for ADME Scientists

Xin Xu, PhD, Senior Scientist, National Center for Advancing Translational Sciences (NCATS), NIH

NCATS ADME Datasets and In Silico Models Derived from These Datasets

Albert Li, PhD, President & CEO at In Vitro ADMET Laboratories 

999Elite Cryopreserved Human Hepatocytes

Peter Tatrai, PhD, Senior Scientist, R&D, Solvo Biotechnology A Charles River  Company

Mechanistic Insights Into the Inhibitor Preincubation Effect

Beth Williamson, PhD, DMPK Project Representative, Early Oncology DMPK, AstraZeneca, UK

Quantitative and Qualitative Aspects of PROTAC Metabolism: Do they differ from small molecule?

Mark Wenlock, PhD, Physical Chemistry Team Leader @ Cyprotex 

High Throughput Physical Chemistry Assays: Advances and Application

Ismael Zamora, PhD, CFO @ Lead Molecular Design, S.L. 

HT-ADME: From Data to Knowledge. Generate Data to Feed AI Model Operation and Reach Optimal Compound Deisgn

Kenneth R. Brouwer, PhD, RPh, Vice President, Technologies-ADME-TOX @ BioIVT

Importance of Polarized Models for the Evaluation of Hepatic Transporter Based Drug Interactions